Exogenous pulmonary surfactant as a drug delivering agent: Influence of antibiotics on surfactant activity

British Journal of Pharmacology

Volumn 118, Issue 3, 1996, Pages 593-598

  Van't Veen, Annemarie ^a   Gommers, Diederik ^a   Mouton, Johan W ^a   Kluytmans, Jan A J W ^a   Krijt, Erik Jan ^a   Lachmann, Burkhard ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

Antibiotics; Antimicrobial agents; Drug delivery; Lung lavage model; Pneumonia; Pulmonary surfactant; Surfactant function

Indexed keywords

AMOXICILLIN; AMPHOTERICIN B; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; CEFTAZIDIME; LUNG SURFACTANT; PENTAMIDINE; TOBRAMYCIN;

ARTERIAL OXYGEN TENSION; ARTICLE; BLOOD GAS; CATTLE; DRUG DELIVERY SYSTEM; GAS EXCHANGE; INTRATRACHEAL DRUG ADMINISTRATION; LUNG LAVAGE; PRIORITY JOURNAL; SURFACE TENSION;

EID: 8944233868     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1476-5381.1996.tb15442.x     Document Type: Article

References (35)

1. BALDWIN, D.R., HONEYBOURNE, D. & WISE, R. (1992). Pulmonary disposition of antimicrobial agents: in vivo observations and clinical relevance. Antimicrobial. Agents Chemother., 36, 1176-1180.
2. BEYER, J., SCHWARTZ, S., BARZEN, G., RISSE, G., DULLENKOPF, K., WEYER, C. & SIEGERT, W. (1994). Use of Amphotericin B aerosols for the prevention of pulmonary aspergillosis. Infection, 22, 143-148.
3. BRAIN, J.D., KNUDSON, D.E., SOROKIN, S.P. & DAVIS, M.P. (1976). Pulmonary distribution of particles given by intratracheal instillation or by aerosol inhalation. Environ. Res., 11, 13-33.
4. CUMMINGS, J.J., HOLM, B.A., HUDAK, M.L., HUDAK, B.B., FERGUSON, W.H. & EGAN, E.A. (1992). A controlled clinical comparison of four different surfactant preparations in surfactant-deficient preterm lambs. Am. Rev. Respir. Dis., 145, 999-1004.
5. VAN DAAL, G.J., BOS, J.A.H., EIJKING, E.P., GOMMERS, D., HANNAPPEL, E. & LACHMANN, B. (1992). Surfactant replacement therapy improves pulmonary mechanics in end-stage influenza A pneumonia in mice. Am. Rev. Respir. Dis., 145, 859-863.
6. VAN DAAL, G.J., SO, K.L., GOMMERS, D., EIJKING, E.P., FIEVEZ, R.B., SPRENGER, M.J., VAN DAM, D.W. & LACHMANN, B. (1991). Intratracheal surfactant administration restores gas exchange in experimental adult respiratory distress syndrome associated with viral pneumonia. Anesth. Analg., 72, 589-595.
7. EIJKING, E.P., VAN DAAL, G.J., TENBRINCK, R., LUIJENDIJK, A., SLUITERS, J.F., HANNAPPEL, E. & LACHMANN, B. (1991). Effect of surfactant replacement on Pneumocystis carinii pneumonia in rats. Intensive Care Med., 17, 475-478.
8. FUJIWARA, T. & ROBERTSON, B. (1992). Pharmacology of exogenous surfactant. In Pulmonary Surfactant: From Molecular Biology to Clinical Practice, ed. Robertson, B., Van Golde, L.M.G. & Batenburg, J.J. pp. 561-592. Amsterdam: Elsevier.
9. GOMMERS, D., VILSTRUP, C., BOS, J.A.H., LARSSON, A., WERNER, O., HANNAPPEL, E. & LACHMANN, B. (1993). Exogenous surfactant therapy increases static lung compliance and cannot be assessed by measurements of dynamic compliance alone. Crit. Care. Med., 21, 567-574.
10. HÄFNER, D., BEUME, R., KILIAN, U., KRASZNAI, G. & LACHMANN, B. (1995). Dose-response comparisons of five lung surfactant factor (LSF) preparations in an animal model of adult respiratory distress syndrome (ARDS). Br. J. Pharmacol., 115, 451-458.
11. HARDIE, W.D., WHEELER, A.P., WRIGHT, P.W., SWINDELL, B.B. & BERNARD, G. (1992). Effect of cyclooxygenase inhibition on amphotericin B-induced lung injury in awake sheep. J. Infect. Dis., 166, 134-138.
12. HOLM, B.A. (1992). Surfactant inactivation in Adult Respiratory Distress Syndrome. In Pulmonary Surfactant: From Molecular Biology to Clinical Practice, ed. Robertson, B., Van Golde, L.M.G. & Batenburg, J.J. pp. 665-684. Amsterdam: Elsevier.
13. IKEGAMI, M., AGATA, Y., ELKADY, T., HALLMAN, M., BERRY, D. & JOBE, A. (1987). Comparison of four different surfactants: in vitro surface properties and responses of preterm lambs to treatment at birth. Pediatrics, 79, 38-46.
14. ILOWITE, J.S., GORVOY, J.D. & SMALDONE, G.C. (1987). Quantitative deposition of aerosolized gentamicin in cystic fibrosis. Am. Rev. Respir. Dis., 136, 1445-1449.
15. JOBE, A.M. (1993). Pulmonary surfactant therapy. N. Engl. J. Med., 328, 861-868.
16. JOBE, A. & IKEGAMI, M. (1987). Surfactant for the treatment of respiratory distress syndrome. Am. Rev. Respir. Dis., 136, 1256-1275.
17. JOHANSSON, J., CURSTEDT, T. & ROBERTSON, B. (1994). The proteins of the surfactant system. Eur. Resp. J., 7, 372-391.
18. KHARASCH, V.S., SWEENEY, T.D., FREDBERG, J., LEHR, J., DAMOKOSH, A.I., AVERY, M.A. & BRAIN, J.D. (1991). Pulmonary surfactant as a vehicle for intratracheal delivery of technetium sulfur colloid and pentamidine in hamster lungs. Am. Rev. Respir. Dis., 144, 909-913.
19. KOBAYASHI, T., KATAOKA, H., UEDA, T., MURAKAMI, S., TAKADA, Y. & KOKABO, M. (1984). Effects of surfactant supplement and end-expiratory pressure in lung lavaged rabbits. J. Appl. Physiol., 57, 996-1001.
20. LACHMANN, B. (1986). New aspects of pathology and therapy of respiratory distress syndrome. In Selected Topics in Perinatal Medicine, ed. Cosmi, E.V. & Di Renzo, G.C. pp. 177-198. Rome: CIC edizione internazionale.
21. LACHMANN, B., FUJIWARA, T., CHIDA, S., MORITA, T., KONISHI, M., NAKAMURA, K. & MAETA, H. (1983). Surfactant replacement therapy in the experimental adult respiratory distress syndrome (ARDS). In Pulmonary Surfactant System, ed. Cosmi, E.V. & Scarpelli, E.M. pp. 231-235. Amsterdam: Elsevier Science Publishers.
22. LACHMANN, B. & GOMMERS, D. (1993). Is it rational to treat pneumonia with exogenous surfactant? Eur. Respir. J., 6, 1437-1438.
23. LACHMANN, B., ROBERTSON, B. & VOGEL, J. (1980). In vivo lung lavage as an experimental model of the respiratory distress syndrome. Acta Anaesth. Scand., 24, 231-236.
24. LACHMANN, B. & VAN DAAL, G.J. (1992). Adult respiratory distress syndrome: Animal models. In Pulmonary Surfactant: From Molecular Biology to Clinical Practice. ed. Robertson, B., Van Golde, L.M.G. & Batenburg, J.J. pp. 635-663. Amsterdam: Elsevier.
25. 99mTc aerosol in normal subjects and in cystic fibrosis patients. Chest, 95, 822-830.
26. LEVINE, S.J., WALSH, T.J., MARTINEZ, A., EICHACKER, P.Q., LOPEZ-BERESTEIN, G. & NATANSON, C. (1991). Cardiopulmonary toxicity after liposomal amphotericin B infusion. Ann. Intern. Med., 114, 664-666.
27. LEWIS, J.F., TABOR, B., IKEGAMI, M., JOBE, A.H., JOSEPH, M. & ABSOLOM, D. (1993). Lung function and surfactant distribution in saline-lavaged sheep given instilled vs. nebulized surfactant. J. Appl. Physiol., 74, 1256-1264.
28. MCCORMACK, J.P. & JEWESSON, P.J. (1992). A critical reevaluation of the 'therapeutic range' of aminoglycosides. Clin. Infect. Dis., 14, 320-339.
29. MINGEOT-LECLERCQ, M.P., LAURENT, G. & TULKENS, P.M. (1988). Biochemical mechanism of aminoglycoside induced inhibition of phosphatidylcholine hydrolysis by lysosomal phospholipases. Biochem. Pharmacol. 37, 591-599.
30. NIKI, Y., BERNARD, E.M., SCHMITT, H-J, TONG, W.P., EDWARDS, F.F. & ARMSTRONG, D. (1990). Pharmacokinetics of aerosol amphotericin B in rats. Antimicrob. Agents Chemother., 34, 29-32.
31. NOTTER, R.H. (1984). Surface chemistry of pulmonary surfactant: the role of individual components. In Pulmonary Surfactant, ed. Robertson, B., Van Golde, L.M.G. & Batenburg, J.J. pp. 17-65. Amsterdam: Elsevier.
32. SAS Users guide. (1990). SAS Institute Inc., Cary NC.
33. SCHÄFER, K.P. (1992). Molecular aspects of lung surfactant proteins and their use as pulmonal carriers. In Drug Targeting and Delivery, ed. Junginger, H.J. pp. 155-166. London: Ellis Horwood Ltd.
34. SPENCER, H. (1985). The bacterial pneumonias. In Pathology of The Lung. pp. 176-213. New York: Pergamon Press.
35. VAN'T VEEN, A., MOUTON, J.W., GOMMERS, D., KLUYTMANS, J.A.J.W., DEKKERS, P. & LACHMANN, B. (1995). Influence of pulmonary surfactant on in vitro bactericidal activities of amoxicillin, ceftazidime, and tobramycin. Antimicrob. Agents Chemother., 39, 329-333.